Halofuginone hydrobromideCAS# 64924-67-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 64924-67-0 | SDF | Download SDF |
| PubChem ID | 132470909.0 | Appearance | Powder |
| Formula | C16H18Br2ClN3O3 | M.Wt | 495.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 7-bromo-6-chloro-3-[3-[(2R,3R)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide | ||
| SMILES | C1CC(C(NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O.Br | ||
| Standard InChIKey | SJUWEPZBTXEUMU-CTHHTMFSSA-N | ||
| Standard InChI | InChI=1S/C16H17BrClN3O3.BrH/c17-11-6-13-10(5-12(11)18)16(24)21(8-20-13)7-9(22)4-14-15(23)2-1-3-19-14;/h5-6,8,14-15,19,23H,1-4,7H2;1H/t14-,15-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Halofuginone hydrobromide Dilution Calculator
Halofuginone hydrobromide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0178 mL | 10.0888 mL | 20.1776 mL | 40.3551 mL | 50.4439 mL |
| 5 mM | 0.4036 mL | 2.0178 mL | 4.0355 mL | 8.071 mL | 10.0888 mL |
| 10 mM | 0.2018 mL | 1.0089 mL | 2.0178 mL | 4.0355 mL | 5.0444 mL |
| 50 mM | 0.0404 mL | 0.2018 mL | 0.4036 mL | 0.8071 mL | 1.0089 mL |
| 100 mM | 0.0202 mL | 0.1009 mL | 0.2018 mL | 0.4036 mL | 0.5044 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Glucovanillin
Catalog No.:BCX1176
CAS No.:494-08-6
- Aloenin B
Catalog No.:BCX1175
CAS No.:106533-41-9
- 7-Oxo-ganoderic acid Z2
Catalog No.:BCX1174
CAS No.:1446104-52-4
- 15-Oxospiramilactone
Catalog No.:BCX1173
CAS No.:1053172-87-4
- Tirotundin 3-O-methyl ether
Catalog No.:BCX1172
CAS No.:1454840-36-8
- Cyaonoside B
Catalog No.:BCX1171
CAS No.:51161-58-1
- Ganolactone A
Catalog No.:BCX1170
CAS No.:173268-82-1
- Guattegaumerine
Catalog No.:BCX1169
CAS No.:21446-35-5
- 25(R)-3β,17α-Dihydroxy-5α-spirostan-6-one 3-O-α-D-rhamnopyranosyl-(1→2)-β-D-glucopyranoside
Catalog No.:BCX1168
CAS No.:143051-94-9
- Hispolon
Catalog No.:BCX1167
CAS No.:173933-40-9
- 6-methoxy-bispyranoxanthone
Catalog No.:BCX1166
CAS No.:115713-10-5
- Aucubigenin
Catalog No.:BCX1165
CAS No.:64274-28-8
- 2-Hydroxypinocembrin
Catalog No.:BCX1178
CAS No.:40489-17-6
- 11-Oxo-ganoderic acid DM
Catalog No.:BCX1179
CAS No.:1408244-15-4
- GDP-L-Fuc.2Na
Catalog No.:BCX1180
CAS No.:15839-70-0
- N-Acetyl-D-lactosamine
Catalog No.:BCX1181
CAS No.:32181-59-2
- Acetylarenobufagin
Catalog No.:BCX1182
CAS No.:184673-79-8
- 5-Methoxyafrormosin 7-O-glucoside
Catalog No.:BCX1183
CAS No.:64656-92-4
- Heterophyllin J
Catalog No.:BCX1184
CAS No.:660397-15-9
- 6-Acetyl-7-hydroxy-2,3-dimethylchromone
Catalog No.:BCX1185
CAS No.:225518-70-7
- Neoisoliquiritigenin
Catalog No.:BCX1186
CAS No.:7014-39-3
- Rubropunctamine
Catalog No.:BCX1187
CAS No.:514-66-9
- Glycyrrhizic acid methyl ester
Catalog No.:BCX1188
CAS No.:104191-95-9
- Kissoone A
Catalog No.:BCX1189
CAS No.:903559-01-3
Inhibition of IL-17 signaling in macrophages underlies the anti-arthritic effects of halofuginone hydrobromide: Network pharmacology, molecular docking, and experimental validation.[Pubmed:38413973]
BMC Complement Med Ther. 2024 Feb 27;24(1):105.
BACKGROUND: Rheumatoid arthritis (RA) is a prevalent autoimmune disease marked by chronic synovitis as well as cartilage and bone destruction. Halofuginone hydrobromide (HF), a bioactive compound derived from the Chinese herbal plant Dichroa febrifuga Lour., has demonstrated substantial anti-arthritic effects in RA. Nevertheless, the molecular mechanisms responsible for the anti-RA effects of HF remain unclear. METHODS: This study employed a combination of network pharmacology, molecular docking, and experimental validation to investigate potential targets of HF in RA. RESULTS: Network pharmacology analyses identified 109 differentially expressed genes (DEGs) resulting from HF treatment in RA. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses unveiled a robust association between these DEGs and the IL-17 signaling pathway. Subsequently, a protein-protein interaction (PPI) network analysis revealed 10 core DEGs, that is, EGFR, MMP9, TLR4, ESR1, MMP2, PPARG, MAPK1, JAK2, STAT1, and MAPK8. Among them, MMP9 displayed the greatest binding energy for HF. In an in vitro assay, HF significantly inhibited the activity of inflammatory macrophages, and regulated the IL-17 signaling pathway by decreasing the levels of IL-17 C, p-NF-kappaB, and MMP9. CONCLUSION: In summary, these findings suggest that HF has the potential to inhibit the activation of inflammatory macrophages through its regulation of the IL-17 signaling pathway, underscoring its potential in the suppression of immune-mediated inflammation in RA.
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.[Pubmed:38190972]
Antiviral Res. 2024 Feb;222:105798.
Halofuginone hydrobromide has shown potent antiviral efficacy against a variety of viruses such as SARS-CoV-2, dengue, or chikungunya virus, and has, therefore, been hypothesized to have broad-spectrum antiviral activity. In this paper, we tested this broad-spectrum antiviral activity of Halofuginone hydrobomide against viruses from different families (Picornaviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, and Flaviviridae). To this end, we used relevant human models of the airway and intestinal epithelium and regionalized neural organoids. Halofuginone hydrobomide showed antiviral activity against SARS-CoV-2 in the airway epithelium with no toxicity at equivalent concentrations used in human clinical trials but not against any of the other tested viruses.
